Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans
Nature Medicine2009Vol. 15(4), pp. 380–383
Citations Over TimeTop 1% of 2009 papers
Hiroshi Watanabe, Nagesh Chopra, Derek R. Laver, Hyun Seok Hwang, Sean S. Davies, Daniel E. Roach, Henry J. Duff, Dan M. Roden, Arthur A.M. Wilde, Björn C. Knollmann
Related Papers
- → Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia(2012)103 cited
- → S4153R Is a Gain-of-Function Mutation in the Cardiac Ca2+ Release Channel Ryanodine Receptor Associated With Catecholaminergic Polymorphic Ventricular Tachycardia and Paroxysmal Atrial Fibrillation(2013)43 cited
- → The Role of Flecainide in the Management of Catecholaminergic Polymorphic Ventricular Tachycardia(2016)22 cited
- → Bradycardia Is a Specific Phenotype of Catecholaminergic Polymorphic Ventricular Tachycardia Induced by <i>RYR2</i> Mutations(2018)24 cited
- → The Role of Flecainide in the Management of Catecholaminergic Polymorphic Ventricular Tachycardia(2016)1 cited